Toma Shamim, Hopkins Claire
ENT Dept, Kennington Road, Willesborough, Ashford, Kent, United Kingdom.
ENT Dept, Guys and St Thomas Hospitals NHS Trust, London, United Kingdom.
Rhinology. 2016 Jun;54(2):129-33. doi: 10.4193/Rhino15.072.
The European Position Paper on Rhinosinusitis and Nasal Polyps provides treatment algorithms based on the mild/moderate/severe (MMS) classification. To date there has been no statistically validated stratification of the SNOT-22 score according to this classification.
65 consecutive patients diagnosed with CRS completed a SNOT-22, VAS and rated their symptoms according to MMS and impact on quality of life.
The median SNOT 22 scores varied between the 3 MMS categories. The interquartile ranges for the respective MMS groups were: Mild 8-17, Moderate 22.5-48, Severe 54-83. Median values for the respective MMs groups were: Mild 12, Moderate 36 and Severe 66. 15.38% of patients in the Mild category, 95.24% in the Moderate category and 100% in the Severe category feel their QoL is affected. There was a strongly positive correlation between the SNOT-22 and VAS scores.
We propose a statistically validated definition for stratification of the SNOT-22, with Mild being defined on the SNOT-22 score as 8-20 inclusive, Moderate as >20-50 and Severe as >50.
《欧洲鼻窦炎和鼻息肉立场文件》提供了基于轻度/中度/重度（MMS）分类的治疗算法。迄今为止，尚未根据该分类对SNOT-22评分进行统计学验证的分层。
65例连续诊断为慢性鼻-鼻窦炎（CRS）的患者完成了SNOT-22、视觉模拟评分（VAS），并根据MMS对其症状进行评分以及评估对生活质量的影响。
SNOT-22评分中位数在3个MMS类别之间有所不同。各MMS组的四分位数间距分别为：轻度8 - 17、中度22.5 - 48、重度54 - 83。各MMS组的中位数分别为：轻度12、中度36、重度66。轻度组中15.38%的患者、中度组中95.24%的患者以及重度组中100%的患者感觉其生活质量受到影响。SNOT-22与VAS评分之间存在强正相关。
我们提出了一种经统计学验证的SNOT-22分层定义，将SNOT-22评分中8至20（含）定义为轻度，>20至50定义为中度，>50定义为重度。
